In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections
- 31 July 2004
- journal article
- research article
- Published by Elsevier BV in Diagnostic Microbiology and Infectious Disease
- Vol. 49 (3), 201-209
- https://doi.org/10.1016/j.diagmicrobio.2004.03.002
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNAJournal of Antimicrobial Chemotherapy, 2004
- In Vitro Activities of Tigecycline against Erythromycin-Resistant Streptococcus pyogenes and Streptococcus agalactiae : Mechanisms of Macrolide and Tetracycline ResistanceAntimicrobial Agents and Chemotherapy, 2004
- In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptidesJournal of Antimicrobial Chemotherapy, 2003
- In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in SpainAntimicrobial Agents and Chemotherapy, 2002
- Glycylcyclines: third-generation tetracycline antibioticsCurrent Opinion in Pharmacology, 2001
- In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamasesDiagnostic Microbiology and Infectious Disease, 2001
- Overcoming Bacterial Resistance by Dual Target Inhibition: The Case of StreptograminsCurrent Drug Targets - Infectious Disorders, 2001
- GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteriaInternational Journal of Antimicrobial Agents, 2001
- In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive BacteriaAntimicrobial Agents and Chemotherapy, 2000
- Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolatesDiagnostic Microbiology and Infectious Disease, 2000